EF-36/Keynote B36: A pilot, randomized, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic non-small cell lung cancer
Details
Age
Adult
Type of Study
Device Feasibility
Locations
Memorial Hospital Central
Memorial Hospital North
Principal Investigator
Robert Hoyer, MD
Study ID
Protocol Number: 21-3694
More information available at ClinicalTrials.gov: NCT04892472
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers